Oxford BioDynamics said it had presented data supporting the use of its bio-marker products at a conference in Washington. The update on the EpiSwitch product was delivered during a plenary talk at the American Society of Hematology Summit on Emerging Immunotherapies for Hematologic Diseases. Chief scientific officer Alexandre Akoulitchev presented data on prognostic blood-based stratifications of patients with a common type of Non-Hodgkin lymphoma, and on predictive bio-markers for response to treatment. Data presented from several indications successfully demonstrated that EpiSwitch bio-markers could help identify patients that would not respond adequately to certain mono-therapies. 'Our aim is to develop and deliver non-invasive prognostic bio-markers in this fast-developing and competitive field, and we were pleased to present strong data at this ASH Summit,' Akoulitchev said. 'Our EpiSwitch technology could stratify and predict which patients would not respond adequately to checkpoint inhibitor therapy, with high accuracy.' 'We are very pleased with the interest our data have generated amongst the leaders in the field.' At 9:21am: (LON:OBD) Oxford Biodynamics Plc share price was -3p at 208p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.